CMRX Archived Articles
Chimerix, Inc. (NASDAQ:CMRX): Advancing Novel Therapies for Rare and Deadly Cancers
Published on March 17, 2025
Chimerix, Inc. (NASDAQ:CMRX): Advancing Dordaviprone for H3 K27M-Mutant Glioma with Promising Regulatory Pathways Emerging
Published on September 24, 2024